|
A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers Clinical research trials and A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers. A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers clinical trial. Subjects frequently get the best healthcare possible for their A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers  A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers
A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers
For Condition: HIV Infections
Status: Completed
Sponsor(s): Genentech ,
Synopsis: To test the safety and immunogenicity of rgp 120/HIV-1IIIB vaccine in HIV-1 seropositive adult patients.
Details:
Eligibility:
Study Type: Interventional, Prevention
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have the following: - Stage 1 or 2 Walter Reed clinical staging of HIV infected individuals. - The ability to understand and sign a written informed consent form, which must be obtained prior to study entry. - Be available for 24 weeks so that follow up may be completed. - Qualify for care as Department of Defense health care beneficiary. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic or autoimmune disease, other than HIV-1 infection, and in less than average general health as determined by a medical history, physical examination, and the required laboratory test results. Concurrent Medication: Excluded: - Corticosteroids or other known immunosuppressive drugs. - Any experimental agents. Patients with the following are excluded: - Prior history of clinically significant cardiac, pulmonary, hepatic, renal, neurologic or autoimmune disease, other than HIV-1 infection, and in less than average general health as determined by a medical history, physical examination, and the required laboratory test results. Prior Medication: Excluded within 30 days of study entry: - Zidovudine or other anti-retroviral agents.
Total Enrollment:
Location and Contact Information:
Walter Reed Army Institute of Research
Rockville, Maryland, 20850
United States
Additional Information:
Study ID Numbers: 075A; V0200g
Study Start Date:
Record last reviewed: August 1992
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001992
Other Hiv Infections Studies:
1. An Oral Dose-Ranging Finding Study in Patients With HIV Disease, CDC Classification Groups IIB, III, and IV-C2
2. Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients
3. Dual Boosted- PI PK trial
4. Blood Levels of Abacavir after One Dose in HIV-Infected Children and Adolescents
5. A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes
Related Studies:
Other HIV Infections Clinical Trials
Other Maryland Clinical Trials
Other Rockville Clinical Trials
A Phase I Study of the Safety and Immunogenicity of rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers
|
|
|
|
|
|
|
|
